{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T22:05:19Z","timestamp":1745359519092},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10157-020-01850-7","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T16:04:36Z","timestamp":1585238676000},"page":"474-482","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination"],"prefix":"10.1007","volume":"24","author":[{"given":"Ya-Wen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Kun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bor-Luen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Shiee","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"1850_CR1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212\u20139.","journal-title":"Vaccine"},{"key":"1850_CR2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355.","journal-title":"Lancet"},{"key":"1850_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97\u2013107.","journal-title":"J Viral Hepat"},{"key":"1850_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1515\/jtim-2015-0018","volume":"3","author":"B Bernieh","year":"2015","unstructured":"Bernieh B. Viral hepatitis in hemodialysis: an update. J Transl Intern Med. 2015;3:93\u2013105.","journal-title":"J Transl Intern Med"},{"key":"1850_CR5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archinte.1979.03630390036015","volume":"139","author":"S Ribot","year":"1979","unstructured":"Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med. 1979;139:178\u201380.","journal-title":"Arch Intern Med"},{"key":"1850_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.12538","volume":"39","author":"C Pipili","year":"2014","unstructured":"Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2014;39:35\u201346.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s10157-018-1676-x","volume":"23","author":"HI Erdogdu","year":"2019","unstructured":"Erdogdu HI, Atalay E, Gursoy G, et al. Factors affecting inadequate response to HBV vaccine in hemodialysis patients: Northeast Anatolia survey with six hemodialysis centers. Clin Exp Nephrol. 2019;23:530\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"1850_CR8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJM197701272960404","volume":"296","author":"Y Pirson","year":"1977","unstructured":"Pirson Y, Alexandre GP, Ypersele C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med. 1977;296:194\u20136.","journal-title":"N Engl J Med"},{"key":"1850_CR9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1034\/j.1399-0012.2002.1o034.x","volume":"16","author":"MK Breitenfeldt","year":"2002","unstructured":"Breitenfeldt MK, Rasenack J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transpl. 2002;16:130\u20136.","journal-title":"Clin Transpl"},{"key":"1850_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257\u201363.","journal-title":"Hepatology"},{"key":"1850_CR11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000046265","volume":"21","author":"WC Lee","year":"2001","unstructured":"Lee WC, Shu KH, Cheng CH, et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol. 2001;21:300\u20136.","journal-title":"Am J Nephrol"},{"key":"1850_CR12","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","volume":"36","author":"TM Chan","year":"2002","unstructured":"Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246\u201352.","journal-title":"Hepatology"},{"key":"1850_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0016-5085(88)90623-3","volume":"94","author":"F Degos","year":"1988","unstructured":"Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: a prospective study of 90 patients. Gastroenterology. 1988;94:151\u20136.","journal-title":"Gastroenterology"},{"key":"1850_CR14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00007890-198709000-00009","volume":"44","author":"JD Harnett","year":"1987","unstructured":"Harnett JD, Zeldis JB, Parfrey PS, et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation. 1987;44:369\u201376.","journal-title":"Transplantation"},{"key":"1850_CR15","first-page":"391","volume":"51","author":"KV Rao","year":"1991","unstructured":"Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991;51:391\u20136.","journal-title":"Transplantation"},{"key":"1850_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007890-199607270-00025","volume":"62","author":"S Fornairon","year":"1996","unstructured":"Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996;62:297\u20139.","journal-title":"Transplantation"},{"key":"1850_CR17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/00007890-198506000-00007","volume":"39","author":"PS Parfrey","year":"1985","unstructured":"Parfrey PS, Forbes RD, Hutchinson TA, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation. 1985;39:610\u20135.","journal-title":"Transplantation"},{"key":"1850_CR18","doi-asserted-by":"crossref","first-page":"21312","DOI":"10.1038\/srep21312","volume":"6","author":"TM Yu","year":"2016","unstructured":"Yu TM, Lin CC, Shu KH, et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: a nationwide population-based cohort study. Sci Rep. 2016;6:21312.","journal-title":"Sci Rep"},{"key":"1850_CR19","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","volume":"66","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66:2715\u201325.","journal-title":"J Antimicrob Chemother"},{"key":"1850_CR20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29:428\u201334.","journal-title":"J Gastroenterol Hepatol"},{"key":"1850_CR21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10157-013-0807-7","volume":"18","author":"YW Yang","year":"2014","unstructured":"Yang YW, Lee CY, Hu RH, Lee PH, Tsai MK. Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients. Clin Exp Nephrol. 2014;18:144\u201350.","journal-title":"Clin Exp Nephrol"},{"key":"1850_CR22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1432-2277.2004.tb00507.x","volume":"17","author":"B Roche","year":"2005","unstructured":"Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int. 2005;17:746\u201358.","journal-title":"Transpl Int"},{"key":"1850_CR23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1432-2277.2000.tb01084.x","volume":"13","author":"D Seehofer","year":"2000","unstructured":"Seehofer D, Rayes N, Berg T, et al. Lamivudine as first-and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int. 2000;13:290\u20136.","journal-title":"Transpl Int"},{"key":"1850_CR24","first-page":"35","volume":"13","author":"C Ruhi","year":"2015","unstructured":"Ruhi C, Suleymanlar I, Kocak H, et al. Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients. Exp Clin Transpl. 2015;13:35\u201340.","journal-title":"Exp Clin Transpl"},{"key":"1850_CR25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","volume":"132","author":"EJ Gane","year":"2007","unstructured":"Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931\u20137.","journal-title":"Gastroenterology"},{"issue":"138\u201346","key":"1850_CR26","first-page":"e5","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146(138\u201346):e5.","journal-title":"Gastroenterology"},{"key":"1850_CR27","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576\u201388.","journal-title":"N Engl J Med"},{"key":"1850_CR28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HL Chan","year":"2012","unstructured":"Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732\u201343.","journal-title":"J Viral Hepat"},{"key":"1850_CR29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s12325-016-0337-2","volume":"33","author":"HL Chan","year":"2016","unstructured":"Chan HL, Shaikh J, Gupta S, Hamed K. Renal function in nucleos(t)ide analog-treated patients with chronic hepatitis B: a systematic literature review and network meta-analysis. Adv Ther. 2016;33:862\u201375.","journal-title":"Adv Ther"},{"key":"1850_CR30","first-page":"9324310","volume":"2017","author":"WC Lee","year":"2017","unstructured":"Lee WC, Wu TH, Wang YC, et al. Renal function improvement by telbivudine in liver transplant recipients with chronic kidney disease. Biomed Res Int. 2017;2017:9324310.","journal-title":"Biomed Res Int"},{"key":"1850_CR31","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.transproceed.2014.07.058","volume":"46","author":"A Perrella","year":"2014","unstructured":"Perrella A, Lanza AG, Pisaniello D, et al. Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function. Transpl Proc. 2014;46:2319\u201321.","journal-title":"Transpl Proc"},{"key":"1850_CR32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jvh.12362","volume":"22","author":"E Cholongitas","year":"2015","unstructured":"Cholongitas E, Vasiliadis T, Goulis I, et al. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat. 2015;22:574\u201380.","journal-title":"J Viral Hepat"},{"key":"1850_CR33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/lt.24131","volume":"21","author":"I Turan","year":"2015","unstructured":"Turan I, Yapali S, Bademkiran F, et al. Telbivudine in liver transplant recipients: renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Transpl. 2015;21:1066\u201375.","journal-title":"Liver Transpl"},{"key":"1850_CR34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00535-012-0676-y","volume":"48","author":"J Aoki","year":"2013","unstructured":"Aoki J, Kowazaki Y, Ohtsuki T, et al. Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. J Gastroenterol. 2013;48:728\u201337.","journal-title":"J Gastroenterol"},{"key":"1850_CR35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/nep.12651","volume":"21","author":"DY Yap","year":"2016","unstructured":"Yap DY, Chan TM. Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: a preliminary experience. Nephrology. 2016;21:438\u201341.","journal-title":"Nephrology"},{"key":"1850_CR36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.13036","volume":"41","author":"S Koklu","year":"2015","unstructured":"Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41:310\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1850_CR37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2307\/2532642","volume":"47","author":"RL Prentice","year":"1991","unstructured":"Prentice RL, Zhao LP. Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses. Biometrics. 1991;47:825\u201339.","journal-title":"Biometrics"},{"key":"1850_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"1850_CR39","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.clinthera.2007.12.032","volume":"29","author":"SJ Matthews","year":"2007","unstructured":"Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007;29:2635\u201353.","journal-title":"Clin Ther"},{"key":"1850_CR40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"CL Lai","year":"2005","unstructured":"Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen\u2014positive chronic hepatitis B. Gastroenterology. 2005;129:528\u201336.","journal-title":"Gastroenterology"},{"key":"1850_CR41","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","volume":"14","author":"XS Zhang","year":"2008","unstructured":"Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol. 2008;14:3549\u201353.","journal-title":"World J Gastroenterol"},{"key":"1850_CR42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","volume":"51","author":"RD Fleischer","year":"2009","unstructured":"Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787\u201391.","journal-title":"J Hepatol"},{"key":"1850_CR43","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/jclinpath-2013-202069","volume":"67","author":"H Xu","year":"2014","unstructured":"Xu H, Wang Z, Zheng L, et al. Lamivudine\/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol. 2014;67:999\u20131005.","journal-title":"J Clin Pathol"},{"key":"1850_CR44","first-page":"863","volume":"6","author":"J Baharin","year":"2014","unstructured":"Baharin J, Sahari NS, Lim SM. Rhabdomyolysis due to lamivudine administration in acute viral hepatitis B infection: a case report from Malaysia. Electron Phys. 2014;6:863\u20137.","journal-title":"Electron Phys"},{"key":"1850_CR45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1743-422X-7-323","volume":"7","author":"J Finsterer","year":"2010","unstructured":"Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J. 2010;7:323.","journal-title":"Virol J"},{"key":"1850_CR46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3350\/cmh.2013.19.1.82","volume":"19","author":"EH Kim","year":"2013","unstructured":"Kim EH, Park H, Lee KH, et al. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol. 2013;19:82\u20136.","journal-title":"Clin Mol Hepatol"},{"key":"1850_CR47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/imj.12237","volume":"43","author":"SW Lee","year":"2013","unstructured":"Lee SW, Jang JH, Kim BJ. Dysphagia could be the first presenting symptom of telbivudine-induced myopathy. Intern Med J. 2013;43:1048\u20139.","journal-title":"Intern Med J"},{"key":"1850_CR48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11255-016-1284-1","volume":"48","author":"A Sidana","year":"2016","unstructured":"Sidana A, Walton-Diaz A, Truong H, et al. Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. Int Urol Nephrol. 2016;48:1047\u201353.","journal-title":"Int Urol Nephrol"},{"key":"1850_CR49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tins.2013.04.008","volume":"36","author":"J Zenker","year":"2013","unstructured":"Zenker J, Ziegler D, Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36:439\u201349.","journal-title":"Trends Neurosci"},{"key":"1850_CR50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/fcp.12002","volume":"28","author":"NG Bb","year":"2014","unstructured":"Bb NG, Sanchez H, Zoll J, et al. Oxidative capacities of cardiac and skeletal muscles of heart transplant recipients: mitochondrial effects of cyclosporin-A and its vehicle Cremophor-EL. Fundam Clin Pharmacol. 2014;28:151\u201360.","journal-title":"Fundam Clin Pharmacol"},{"key":"1850_CR51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bjp.0704129","volume":"133","author":"H Sanchez","year":"2001","unstructured":"Sanchez H, Zoll J, Bigard X, et al. Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain. Br J Pharmacol. 2001;133:781\u20138.","journal-title":"Br J Pharmacol"},{"key":"1850_CR52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12985-016-0522-6","volume":"13","author":"X Wu","year":"2016","unstructured":"Wu X, Cai S, Li Z, et al. Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virol J. 2016;13:64.","journal-title":"Virol J"},{"key":"1850_CR53","doi-asserted-by":"crossref","first-page":"e32528","DOI":"10.5812\/hepatmon.32528","volume":"16","author":"L Jiang","year":"2016","unstructured":"Jiang L, Hu S, He M, Tian D. Estimated glomerular filtration rate increases in chronic hepatitis B patients treated with telbivudine monotherapy and combination treatment. Hepat Mon. 2016;16:e32528.","journal-title":"Hepat Mon"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-020-01850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:48:45Z","timestamp":1616719725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-020-01850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01850-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"6 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was approved by the ethics committee of National Taiwan University Hospital in July 2014 (IRB Approval No. 201310070MINA), and all study procedures adhered to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}